Every material Form 8-K PharmaCyte Biotech, Inc. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PharmaCyte Biotech received a Nasdaq notice on December 1, 2025, saying its common stock no longer meets the $1.00 minimum bid price for continued listing on the Nasdaq Capital Market. The notice has no immediate effect on listing or trading, and the company has until June 1, 2026 to regain compliance, which matters to shareholders because continued failure could lead to delisting.
Nasdaq notice dated December 1, 2025 cites failure to meet the $1.00 minimum bid price under Listing Rule 5550(a)(2)
Compliance Date is June 1, 2026, a 180-day period; regaining compliance requires at least $1.00 closing bid for 10 consecutive business days
Stock continues to trade under PMCB; the company may seek a second 180-day period or consider a reverse stock split subject to stockholder approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PharmaCyte Biotech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →